Halozyme Therapeutics (HALO) Work In Process (2011 - 2026)

Halozyme Therapeutics (HALO) has 16 years of Work In Process data on file, last reported at $35.0 million in Q1 2026.

• On a quarterly basis, Work In Process fell 4.4% year-over-year to $35.0 million in Q1 2026; TTM through Mar 2026 was $35.0 million, a 4.4% decrease from a year earlier, with the FY2025 full-year figure at $30.9 million, up 2.49% from the prior year.
• Work In Process for Q1 2026 stood at $35.0 million, up from $30.9 million in the prior quarter.
• Over the last five years, Work In Process for HALO reached as high as $56.2 million in Q3 2022 and fell as low as $6.3 million in Q1 2022.
• Historically, Work In Process has averaged $34.9 million across 5 years, with a median of $35.0 million in 2026.
• Across the five-year window, Work In Process tumbled 67.43% in 2022 and jumped 332.75% in 2023, its largest moves.
• Year by year, Work In Process stood at $44.1 million in 2022, then declined by 22.85% to $34.0 million in 2023, then decreased by 11.33% to $30.2 million in 2024, then rose by 2.49% to $30.9 million in 2025, then grew by 13.32% to $35.0 million in 2026.
• Per Business Quant data, the three most recent Work In Process figures were $35.0 million in Q1 2026, $30.9 million in Q4 2025, and $34.8 million in Q3 2025.